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Abstract: 
States of growth hormone (GH) resistance, such those observed in Laron’s dwarf patients, are 
characterized by mutations in the GH receptor (GHR), decreased serum and tissue IGF-1 levels, impaired 
glucose tolerance, and impaired skeletal acquisition. IGF-1 replacement therapy in such patients increases 
growth velocity but does not normalize growth. Herein we combined the GH-resistant (GHR knockout, 
GHRKO) mouse model with mice expressing the hepatic Igf-1 transgene (HIT) to generate the GHRKO-
HIT mouse model. In GHRKO-HIT mice, serum IGF-1 levels were restored via transgenic expression of 
Igf-1, allowing us to study how endocrine IGF-1 affects growth, metabolic homeostasis, and skeletal 
integrity. We show that in a GH-resistant state, normalization of serum IGF-1 improved body adiposity 
and restored glucose tolerance but was insufficient to support normal skeletal growth, resulting in an 
osteopenic skeletal phenotype. The inability of serum IGF-1 to restore skeletal integrity in the total 
absence of GHR likely resulted from reduced skeletal Igf-1 gene expression, blunted GH-mediated effects 
on the skeleton that are independent of serum or tissue IGF-1, and from poor delivery of IGF-1 to the 
tissues. These findings are consistent with clinical data showing that IGF-I replacement therapy in 
patients with Laron’s syndrome does not achieve full skeletal growth. 
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Introduction: 
 
The insulin-like growth factor (IGF)-1 and its receptor IGF-1R play a major role in tissue homeostasis 
during embryogenesis, development and pre-pubertal growth (1). IGF-1 acts both in endocrine and 
autocrine/paracrine fashions (2). The endocrine/circulating IGF-1, secreted by the liver, is mainly 
regulated by GH, whereas the autocrine/paracrine (tissue) IGF-1 is regulated by tissue-specific factors (3). 
In the circulation, IGFs bind to IGF-binding proteins (IGFBPs), which regulate their interaction with IGF-
1R (3, 4). More than 90% of circulating IGF-1 is complexed with IGFBP-3 and an acid labile subunit 
(ALS) (5). Binding to IGFBPs and the ALS stabilizes IGF-1 in serum and regulates its bioavailability (5). 
 
In the past few years, several groups, including ours, have focused their efforts on understanding the 
biological roles of each mode of IGF-1 in the whole body and skeletal growth. Studies in mice with a 
liver-specific gene deletion of Igf-1 (LID) ((6)) or a null mutation in Als (ALSKO) (7, 8), in which serum 
IGF-1 levels are dramatically decreased, revealed only minor changes in linear growth, suggesting that 
tissue IGF-1 plays a major role in the determination of body size. An elegant study by Stratikopoulos et 
al. showed that in Igf-1 null mice (devoid of tissue IGF-1), endocrine IGF-1 was partially restored (~50% 
of normal) by re-expression of the Igf-1 gene in the liver (9). Characterization of those mice revealed 
partial restoration of body and skeletal size. Using a different strategy, we generated the KO-HIT mouse, 
where the sole source of endocrine IGF-1 production in the Igf-1 null background was a rat Igf-1 
transgene expressed in the liver (HIT) (10). In this model, serum IGF-1 levels were 2-fold greater than 
controls, and, interestingly, body size and skeletal properties were restored starting at 8 weeks of age (11). 
Nonetheless, during early development (before 8 weeks), significant reductions in both body and skeletal 
size were evident in the KO-HIT mice, again suggesting that tissue IGF-1 plays a crucial role in 
determining body and skeletal size. However, increases in serum IGF-1 could permit post-pubertal “catch 
up” growth. Importantly, however, overexpression of the Igf-2 transgene under the control of a PEPCK 
promoter in the liver of Igf-1 null mice resulted in increased circulating levels of IGF-2 but failed to 
restore growth (12). These findings suggest that despite the structural/functional similarities and despite 
the fact that their effects are mediated by the same IGF-1 receptor, IGF-1 and IGF-2 have distinct 
functions, and only treatment with the former is capable of restoring postnatal growth in a murine model 
system. 
 
In the current study, we aimed to characterize the contribution of GH to skeletal growth and integrity. To 
that end, we generated the GHRKO-HIT mouse model in which Ghr was ablated in all tissues and the 
sole source of IGF-1 was the previously described hepatic Igf-1 transgene (HIT) (10). Our new data 
suggest that GH actions in extrahepatic tissues are vital for the establishment of body size and skeletal 
integrity. 
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Results: 
 
Generation and validation of the GHRKO-HIT mouse model. 
In our previous studies, we showed that the hepatic Igf-1 transgene (HIT) driven by the transthyretin 
(TTR) promoter was able to restore postnatal growth in the Igf-1 null mice (KO-HIT mouse model), such 
that their body size was indistinguishable from controls (10). Interestingly, however, despite the 2-fold 
increase in serum IGF-1 levels observed in the KO-HIT mice, GH levels remained normal (10). Thus, we 
could not rule out direct effects of GH on body size that are independent of tissue IGF-1. We therefore 
developed a new mouse model in which the hepatic Igf-1 transgene (HIT) driven by the transthyretin 
(TTR) promoter (Figure 1A) was expressed in Ghr null background (GHRKO-HIT). This was achieved 
via the crossing strategy depicted in Figure 1B.  
 
Gene expression studies in liver, muscle and fat showed that the rat Igf-1 transgene was expressed 
specifically in the livers of HIT and GHRKO-HIT mice but absent in all other tissues (Figure 1C). As 
expected, expression of the Ghr gene was detected in the liver, muscle and fat of all groups except the 
GHRKO and GHRKO-HIT mice. Likewise, expression of the Als gene, a surrogate marker of GH action, 
was decreased in the liver, muscle and fat of GHRKO and GHRKO-HIT mice. Expression of the 
endogenous mouse Igf-1 (MmIgf-1) gene was detected in liver, muscle and fat, but, as expected, reduced 
levels were found in tissues of GHRKO and GHRKO-HIT mice (Figure 1C).  
 
GHR action is essential for the establishment of body size. 
Postnatal growth of control (WT), HIT, GHRKO and GHRKO-HIT mice was assessed by body weight 
and body length in both males (Figure 2A, C) and females (Figure 2B, D) on two genetic backgrounds: 
C57Bl6/J (Figure 2A, B) and FVB/N (Figure 2C, D). As expected, both male and female GHRKO mice 
showed impaired growth and were significantly smaller than control mice on both the FVB/N and 
C57Bl6/J genetic backgrounds. HIT mice, on the other hand, showed a significant increase in body 
weight on the FVB/N genetic background (Figure 2C, D), as previously described (10, 11). On the 
C57Bl6/J genetic background, the body weight of HIT mice did not differ from that of control mice 
during 16 weeks (Figure 2A, B). Surprisingly, postnatal growth of the GHRKO-HIT mice was retarded in 
both genders on both genetic backgrounds. GHRKO-HIT mice exhibited reduced body weight (by 40%) 
through 16 weeks of postnatal growth. These striking results show that in the absence of tissue GHR 
activity, serum IGF-1 is insufficient to restore normal growth and development, implying that tissue GHR 
is the master regulator of body size.  
 
Further characterization of these mouse models was performed on the C57Bl6/J genetic background. As 
with body weight, the body lengths of GHRKO mice were shorter than those of controls (Table 1), while 
HIT mice were similar to controls on the C57Bl6/J genetic background. Both male and female GHRKO-
HIT mice, on the other had, were shorter than controls but longer than GHRKO mice.  Interestingly, we 
also detected changes in body composition. Quadriceps weight was decreased in GHRKO mice, whereas 
normalization of serum IGF-1 levels in the GHRKO-HIT mice was associated with increased quadriceps 
weight (Table 1). Similarly, as previously described (13), relative liver weight was reduced in GHRKO 
mice, whereas expression of the rat Igf-1 transgene in the GHRKO-HIT mice normalized relative liver 
weight (Table 1). In accordance with previous studies (13), GHRKO mice exhibited increases in the 
weight of both gonadal and brown fat pads (Table 1, Figure 2E). Normalization of serum IGF-1 levels 
(GHRKO-HIT) resulted in significant reductions in gonadal fat pad weight but did not influence the 
volume of brown adipose tissue. These data strongly suggest that GH regulates gonadal fat via liver-
derived IGF-1. 
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GHR regulates the endocrine pool of IGF-1. 
As previously described (13), serum IGF-1 levels were significantly decreased in GHRKO mice 
compared with controls (14.57+/-2.48 ng/ml vs. 292+/-13 ng/ml, respectively). In contrast, expression of 
the hepatic Igf-1 transgene (HIT) under the TTR promoter led to a 2-fold increase in serum IGF-1 levels 
(648+/-49 ng/ml vs. 292+/-13 ng/ml in controls), consistent with our previous observations (10, 11) 
(Figure 3A). However, despite harboring the same rat HIT transgene, serum IGF-1 levels in GHRKO-HIT 
mice were not elevated but were instead comparable to those of control mice (320+/-1 ng/ml vs. 292+/-13 
ng/ml, respectively).  
 
To understand why serum IGF-1 levels were not elevated in the GHRKO-HIT mice, we measured serum 
levels of the IGFBPs and ALS, which stabilize IGF-1 in serum. Because hepatic Als gene expression was 
reduced in the GHRKO-HIT mice (Figure 1C), we speculated that it would show correspondingly reduced 
levels in the circulation. Indeed, as determined by a Western immunoblot assay, ALS was undetectable in 
the serum of GHRKO and GHRKO-HIT mice (Figure 3B). Surprisingly, this pattern correlated with 
reduced serum levels of IGFBP-3 in both GHRKO and GHRKO-HIT mice (Figure 3C), despite 
unchanged levels of hepatic Igfbp-3 gene expression (Figure 1C). Together, these results suggest that the 
absence of elevated serum IGF-1 levels in GHRKO-HIT mice can be attributed to decreased IGF-1 
complex stability and that GHR regulates the pool of IGF-1 in serum by virtue of its control of als gene 
expression. It is important to note that both HIT and GHRKO-HIT mice harbor multiple copies of the rat 
Igf-1 transgene, which is constitutively expressed under the TTR promoter and thus is not regulated by 
GH. This may explain why there is a constant hepatic production and secretion of IGF-1 to the circulation 
reaching control levels.  
 
Consequently, we examined the ability of serum from GHRKO, GHRKO-HIT, and HIT mice to support 
the formation of ternary complexes with 125I-IGF-1. This assay provides only qualitative information 
about the presence of the three serum components required for IGF-1 ternary complex formation, namely 
IGF-1, a binding protein and ALS. Importantly, the percent binding observed in the different fractions 
does not reflect the absolute concentration of any of the components. As presented in Figure 3D and E, 
ternary complex formation (fractions 0-10) was significantly reduced in sera from GHRKO and GHRKO-
HIT mice, suggesting significant reductions in the levels of IGFBPs and ALS, as previously demonstrated 
(Figure 3B, C). However, IGF binary complexes (fractions 20-30) were present in all groups, including 
GHRKO, GHRKO-HIT, HIT and controls. These data suggest that in both GHRKO and the GHRKO-HIT 
mice, most of the serum IGF-1 is found in binary complexes with IGFBPs (other than IGFBP-3) or as a 
free peptide. 
 
Normalization of serum IGF-1 levels is insufficient to restore skeletal growth in the complete 
absence of tissue GHR. 
Skeletal characterization of GHRKO-HIT mice on the C57Bl6/J genetic background was performed on 
femurs dissected at 16 weeks of age. As previously described (13), GHRKO mice showed significant 
decreases in all bone structural traits compared with control mice (Tables 2, 3). These included reductions 
in femoral length (by 30%), total cross-sectional area (Tt.Ar; by 53%), cortical area (Ct.Ar; by 60%), 
cortical thickness (Ct.Th; by 40%) and polar moment of inertia (J0; by 80%). Cross-sectional areas of 
GHRKO femora were also smaller than controls when normalized to bone length i.e., robustness 
(Tt.Ar/Le) (Table 2), indicating that total inactivation of GHR action produced a slender bone phenotype.  
 
Our previous characterization of the HIT mouse model was performed in mice on the FVB/N genetic 
background (10, 11) and revealed significant increases in body size. However, on the C57Bl6/J genetic 
background, HIT mice do not exhibit increases in body size, and as a result, their skeletal phenotype at 16 
weeks is similar to that of controls. It is conceivable that this discrepancy stems from genetic background 
differences.  
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Interestingly, normalization of serum IGF-1 levels failed to restore postnatal skeletal growth in GHRKO-
HIT mice. GHRKO-HIT mice exhibited significantly shorter femora (20% decrease), reduced Tt.Ar (35% 
decrease) and cortical area (Ct.Ar; 30% decrease) and more slender, less robust bones (reduced Tt.Ar/Le) 
at 16 weeks of age compared with controls. Nonetheless, compared with GHRKO mice, we found that 
Tt.Ar, Ct.Ar, and Ct.Th were increased in GHRKO-HIT mice, whereas marrow area (Ma.Ar) did not 
differ significantly between GHRKO and GHRKO-HIT mice. This indicates that normalization of serum 
IGF-1 levels in GHRKO-HIT mice increased bone tissue area (Ct.Ar) and enhanced periosteal bone 
apposition.  
 
Unlike the significant differences observed in the cortical shell of GHRKO vs. GHRKO-HIT mice, the 
trabecular bone phenotype at the distal femur was not different between the 2 groups (GHRKO and 
GHRKO-HIT) in male mice. However, it should be noted that both GHRKO and GHRKO-HIT mice 
show reductions in trabecular bone volume compared with control and HIT mice. In female mice 
however, we found an increase in BV/TV% and in BMD in the GHRKO-HIT mice as compared to the 
GHRKO mice (Table 3). The cellular or molecular mechanisms responsible for that increase are unclear 
and require further investigation. 
 
To better understand the cellular mechanisms that lead to the GHRKO-HIT phenotype, we measured 
serum levels of osteocalcin, a bone formation marker. We found no significant differences between 
controls (53+/-17 ng/ml), GHRKO (49+/-18 ng/ml), GHRKO-HIT (49+/-15 ng/ml), or HIT (54+/-9 
ng/ml) mice. We thus explored whether the kinetics of bone apposition differed between the groups using 
dynamic histomorphometry (Table 4, Figure 4). We found that the mineralized surface/bone surface 
(MS/BS) decreased in GHRKO mice at both the endosteal and periosteal surfaces as compared to 
controls. In contrast, GHRKO-HIT mice showed an increase in %MS/BS on both surfaces when 
compared to GHRKO mice. Calculations of mineral apposition rates (MAR) and bone formation rates 
(BFR) on both the endosteal and periosteal surfaces revealed large variability within the groups and thus 
did not reach significance. Nonetheless, we found that the MAR and BFR in both endosteal and periosteal 
surfaces decreased in GHRKO mice and reached control rates in GHRKO-HIT mice. HIT mice, however, 
tended to increase MAR and BFR at the endosteal surface as compared to control mice, while MAR and 
BFR at the periosteal surface were similar to controls. These data are in accordance with our previous 
findings (11), suggesting that increases in serum IGF-1 levels are associated with increased MAR and 
BFR. Overall our dynamic histomorphometry findings are in accordance with the morphology data 
obtained by mCT (Table 3).  
 
The impaired skeletal phenotype in the GHRKO mice attributed to global reductions in IGF-1 (in both 
serum and tissues) as well as to IGF-1-independent effects of GH on the skeleton (14). Thus, we assessed 
the levels of skeletal Igf-1 gene expression in femoral cortices of control, GHRKO, GHRKO-HIT and 
HIT mice at 16 weeks of age. Skeletal Igf-1 gene expression significantly reduced in GHRKO mice and 
was not restored in GHRKO-HIT mice (Figure 5A). As expected, Ghr gene expression was undetectable 
in both GHRKO and GHRKO-HIT mice (Figure 5B). Overall, these data suggest that one of the reason 
for the impaired skeletal growth in the GHRKO-HIT mice is likely the low levels of skeletal Igf-1 
production that were not restored with expression of the hepatic Igf-1 transgene.     
 
Normalization of serum IGF-1 levels in the complete absence of GHR is sufficient to restore glucose 
tolerance in GHRKO mice. 
GH affects multiple tissues, and its role in carbohydrate and lipid metabolism has been extensively 
investigated. GHRKO mice exhibit an enhanced insulin sensitivity reflected by decreases in serum levels 
of basal glucose and insulin (13). However, when challenged with a bolus of glucose, GHRKO mice 
exhibit impaired glucose clearance due to reduced β-cell mass and consequent reductions in insulin 
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secretion (15). To address whether normalization of serum IGF-1 levels in GHRKO mice improved 
glucose tolerance, we measured insulin levels in serum and performed a glucose tolerance test (GTT). As 
expected, glucose tolerance was impaired in GHRKO mice and correlated with reduced β-cell mass 
(Figure 6). However, normalization of serum IGF-1 in GHRKO-HIT mice was associated with 
normalized GTT. This could be partially explained by increased β-cell mass compared with GHRKO 
mice (Figure 6).  
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Discussion: 
In this study, we present a mouse model of GH resistance that, despite normal levels of serum IGF-1, 
shows significant growth retardation. We show that in a GH resistance state, normalization of serum IGF-
1 levels improved body adiposity and restored glucose tolerance but was insufficient to support normal 
skeletal growth, resulting in an osteopenic bone phenotype. We show that skeletal Igf-1 gene expression 
significantly reduced in states of GH resistance and that serum IGF-1, although found in normal levels 
(GHRKO-HIT mice), is not bound to IGFBP-3 and ALS.  
 
The GHR null (GHRKO) mice were generated over a decade ago and have proven to be a useful and 
suitable mammalian model for studying human Laron syndrome (16). The GHR defects that cause Laron 
syndrome are heterogeneous and include gene deletions and point mutations (17-19), but all are 
characterized by receptor inactivation and inhibition of downstream signaling pathways. This results in 
the failure to generate IGF-1 in response to endogenous or exogenous GH, which consequently leads to 
short stature, delayed bone age and bone maturation. Laron’s patients are resistant to GH treatment. 
However, cells isolated from these patients respond to insulin and IGF-1 (20), suggesting that the insulin 
and IGF-1 receptors are intact and active. Based on these in vitro data, several clinical studies verified the 
effects of recombinant IGF-1 treatment on skeletal growth in Laron dwarfs. Most studies (21-31) indicate 
a rapid increase in linear growth and height velocity during the first year of treatment, along with 
decreases in body adiposity. However, IGF-1 treatment did not normalize overall growth. Our study 
design resembles IGF-1 replacement therapy in Laron’s dwarfs in that serum IGF-1 levels were restored 
via transgenic expression.  As with Laron’s dwarfs, we show here that skeletal GHR activity is vital for 
the establishment of normal growth. 
 
GH is the primary regulator of ALS transcription in the liver (32). Deficiencies in GHR action in the liver 
lead to almost complete ablation of ALS expression and result in significant reductions in the formation 
of the IGF-1 ternary complex (ALS/IGFBP3/IGF-1), which is obligatory for effective IGF-1 delivery to 
tissues. In our previous study we have shown that serum IGF-1 levels decreased significantly in the 
ALSKO/BP3KO double knockout mice (5). In these mice the two endogenous copies of the Igf-1 gene are 
expressed under IGF-1 regulated promoter and reductions in serum IGF-1 levels result likely from rapid 
degradation of the peptide in serum. In the GHRKO-HIT mouse model presented herein, serum IGF-1 
levels were restored to normal levels. However, in the GHRKO-HIT mouse model, the Igf-1 transgene 
presents in multiple copies and is constantly expressed under the TTR promoter, which is not regulated by 
GH. The normal level of IGF-1 in serum of GHRKO-HIT mice are likely the result of a constant high 
output of the peptide to circulation and possibly increases in the levels of IGFBPs (other than IGFBP3) 
and binary complex formation. 
 
Our data suggest that serum IGF-1 in the GHRKO-HIT mice, which likely delivered to target tissues via 
binary complexes with IGFBPs, increase β-cell mass of GHRKO-HIT mice, leading to normal glucose 
tolerance. These data are also in agreement with a previous study (33) showing that ubiquitous restoration 
(via the metallothionein I promoter) of Igf-1 gene expression in GHRKO mice restored their β-cell mass 
and glucose tolerance.  Here, we show that normalization of endocrine IGF-1 is in fact sufficient to 
restore glucose tolerance in a state of GHR resistance. Additionally, we show that normalization of IGF-1 
levels was associated with reduced subcutaneous and gonadal fat pad weights, which may indirectly lead 
to enhanced insulin sensitivity. 
 
Our previous studies with the LID (6) and Als null (ALSKO) mice (7), where serum IGF-1 levels were 
dramatically decreased, demonstrated that the GH/IGF-1 axis not only regulates linear bone growth but 
also controls the development of the diaphysis and thus has major effects on bone strength. Likewise, LID 
mice have more slender bones with reduced stiffness and reduced bending strength due to significant 
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decreases in femoral total area (Tt.Ar) and cortical area (Ct.Ar) beginning at 8 weeks of age (8). The 
reductions in serum IGF-1 levels affected the cortical shell and prevented periosteal bone apposition 
during growth. The ALSKO mice show reductions in body weight and body length throughout growth (5) 
as well as slender bones with reduced Tt.Ar, Ct.Ar, and marrow area (Ma.Ar). The data from the LID and 
ALSKO models suggested that serum IGF-1 levels regulate periosteal bone apposition during growth. 
However, in LID mice, the reductions in serum IGF-1 levels led to increases in GH secretion, which could 
have direct compensatory effects on bone. Indeed, in a related study (34), we demonstrated that inhibition 
of GH action in LID mice resulted in significant reductions in Ct.Ar, indicating that antagonizing GH 
action caused deep reductions in the amount of cortical bone formed, leading to slender, mechanically 
inferior bones. To better understand the interplay between GH and IGF-1 in the skeleton, we previously 
generated transgenic mice with hepatocyte-specific expression of rat Igf-1 (HIT). These mice show 
elevations in serum IGF-1 levels that lead to increases in body weight and femoral length, Tt.Ar, Ct.Ar, 
cortical thickness (Ct.Th), and Jo (11). When HIT mice were crossed to the IGF-1 null mice (IGF-1KO-
HIT), serum IGF-1 levels increased ~2-fold, and skeletal growth normalized. IGF-1KO-HIT mice 
exhibited normal bone length, and in adults (16 weeks), the femoral cross-sectional area reached control 
levels (11). However, it should be noted that in the IGF-1KO-HIT mice, serum GH levels were normal, 
and the GHR pathway in bone was intact. Further, although skeletal igf-1 gene expression was ablated 
(due to the lack of the Igf-1 gene), circulating IGF-1 was bound to IGFBP-3 and ALS and was properly 
delivered to tissues. In sharp contrast, when Ghr gene was ablated, the same HIT transgene (GHRKO-
HIT) was unable to restore growth. GHRKO-HIT mice displayed retarded linear growth and reduced 
transversal bone growth as indicated by smaller Tt.Ar values.  In the GHRKO-HIT mice (as in the IGF-
1KO-HIT) (i)-skeletal Igf-1 gene expression was blunted, (ii)-the GHR pathway was ablated (due to the 
lack of the Ghr gene), and (iii)-serum IGF-1 was not delivered bound in ternary or binary complexes with 
IGFBP-3 and ALS to tissues. Taken together the GHRKO-HIT and IGF-1KO-HIT mouse models, we 
suggest that IGF-1-independent actions of GH on the skeleton are vital for establishment of skeletal size 
and integrity and cannot be fully compensated for by increasing serum IGF-1 levels. Our findings are 
consistent with clinical studies reporting that Laron’s dwarf patients treated with recombinant IGF-1 do 
not reach normal height. They do, however, show improvement in height and growth velocity in response 
to treatment. Thus, in states of GHR resistance, strategies to increase skeletal expression of Igf-1 and 
improvement of IGF-1 delivery to tissues should be carefully considered to achieve better anabolic effects 
on the skeleton. 
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Methods: 
Animals 
HIT mice (on the FVB/N) were generated as described previously (10). To establish a HIT mouse line on 
a C57Bl6/J background we have crossed the HIT-FVB/N mice 8 generations to wild-type C57Bl6/J mice. 
HIT mice were crossed to GHRKO mice (on the FVB/N or C57Bl6/J background) as described in Figure 
1B. HIT and GHRKO-HIT mice were homozygous for the Igf-1 transgene. Mice were housed 4 per cage 
in a clean mouse facility, fed standard mouse chow (Purina Laboratory Chow 5001; Purina Mills) and 
water ad libitum, and kept on a 12 hour light:dark cycle. Animal care and maintenance were provided 
through NYU’s AAALAC Accredited Animal Facility. All procedures were approved by the Animal Care 
and Use Committee of NYU.  
 
Serum hormones 
Mice were bled between 7-9 AM through the mandibular vein before sacrifice. Serum samples were 
collected in a fed state at 16 weeks of age. Serum IGF-1 was measured by RIA (American Laboratory 
Products Company, Inc., Salem, NH, USA). Serum GH and IGFBP-3 levels were determined using 
commercial ELISA kits (Millipore, Temecula, CA, USA).  
 
For measurement of ALS, sera were diluted 1:4 with saline and subsequently separated on a 4-12% 
acrylamide gel and transferred to nitrocellulose. Membranes were blocked with LI-COR block solution 
(Lincoln, NE, USA) and incubated overnight at 4°C with a goat anti-ALS antibody (R&D Systems, Inc., 
Minneapolis, MN USA).  Following washing, the membrane was incubated with IRDye800CW-donkey 
anti-goat antibody (LI-COR, Lincoln, NE, USA).  Bound antibodies were detected by the LI-COR 
Odyssey infrared imaging system (LI-COR). 
 
Formation of IGF complexes was performed in accordance to the protocol adopted from Baxter et al.(35). 
Serum samples (100 µl) were incubated overnight at 22°C with I125-IGF-1 (at a final concentration of 10 
ng/ml) and then cross-linked with disuccinimidyl suberate as reported previously (36). Complexes were 
separated using HiPrep 16/60 Sephacryl S-200HR columns and 1-ml fractions were collected and 
counted. 
 
Glucose tolerance test 
Glucose (2 g/kg) was injected intraperitoneally to overnight-fasted mice. Glucose levels were measured in 
the tail vein at the indicated time points using an automatic Glucometer Elite (Bayer, Elkhart, IN).  
 
MicroComputed Tomography 
Cortical bone morphology at the mid-femoral diaphysis and trabecular bone volume fraction and 
microarchitecture in the excised distal femoral metaphysis were assessed as previously described (37) and 
according to JBMR guidelines (38). Femora were reconstructed at a 6 μm voxel resolution. For trabecular 
bone regions, we assessed the bone volume fraction (BV/TV, %), trabecular thickness (Tb.Th, µm), 
trabecular number (Tb.N), and trabecular spacing (Tb.Sp, µm). For cortical bone at the femoral midshaft, 
we measured the average total cross-sectional area inside the periosteal envelope (Tt.Ar, mm2), the 
cortical bone and medullary area within this same envelope (Ct.Ar, mm2 and Ma.Ar mm2, respectively), 
the relative cortical area (RCA; Ct.Ar/Tt.Ar, %), the average cortical thickness (Ct.Th, µm) and the polar 
moment of inertia (Jo). All regions of analysis were standardized according to anatomical landmarks.  
 
Histomorphometry 
Sixteen-week-old animals were injected twice with calcein (15 mg/Kg) with >10 days between the two 
injections (in the case of GHRKO and GHRKO-HIT mice the interval between the two injections was 17-
23 days). Femora were fixed in 10% neutral buffered formalin, embedded in polymethylmethacrylate 
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(PMMA) and sectioned (80 µm thickness) at the mid-diaphysis using a low-speed diamond-coated 
wafering saw (Leica, Bannockburn, IL, USA).  Sections were adhered to either glass or acrylic slides 
using a nonfluorescing mounting medium. Final section thicknesses after polishing were between 30 and 
40 μm. All measurements were performed using an OsteoMeasure system (Osteometrics, Atlanta, GA, 
USA) in accordance with standard protocols. Sections were imaged using a digital camera attached to a 
visible light/fluorescence microscope (Zeiss Axioplan2, Zeiss AxioVision, Thornwood, NY). 
 
Histology 
Tissues were fixed in 10% buffered formalin phosphate (Fisher Scientific) and embedded in paraffin. 
Immunohistochemistry with rabbit anti-human insulin (Cell Signaling #C27C9) was performed in 5-um 
sections of paraffin-embedded pancreata. -cell mass was calculated from 3-5 pancreatic sections per 
mouse stained with the anti-insulin antibody. Relative β cell area was calculated using NIH Image J 
software, and β-cell mass was calculated as the β-cell relative area multiplied by the pancreatic weights of 
6 mice per group.  
 
Gene expression studies 
Total RNA was extracted from tissues using TRIzol (Invitrogen, Carlsbad, CA). RNA samples (1 μg) 
were reverse-transcribed using oligo-(dT) primers (Invitrogen), and quantitative real-time PCR was 
performed following the manufacturer’s instructions using the QuantiTectTM SYBR® green PCR kit 
(Qiagen, Valencia, CA, USA) on an ABI PRISM 7900HT sequence detection system (Applied 
Biosystems, Foster City, CA, USA). Transcript levels were assayed 3 times in each sample, and the fold-
change ratios between experimental and control samples were calculated relative to β-actin, GAPDH or 
18S. 
 
Statistical analysis 
All differences in mean serum hormone levels, organ weights, and growth among the different groups 
were assessed by analyses of variance (ANOVA). Values are presented as the mean ± S.E., and P < 0.05 
was considered statistically significant. All micro-CT measurements are presented as the mean ± S.D. One-
way ANOVAs were used to test for differences among groups (Statview software version 5.0, SAS 
Institute Inc.). If the ANOVA revealed significant effects, the means were compared by Fisher’s test, 
considering P<0.05 as significant.  
 
 12
 
Acknowledgments: 
Shoshana Yakar is the principle investigator on the study and as such designed and oversaw all the 
experiments, data collection, and data analyses. Dr. Yakar also wrote the manuscript. Dr. Yingjie Wu and 
Mrs. Hui Sun collected the data and performed the metabolic studies. Mrs. Jelena Basta-Pljakic and Dr. 
Luis Cardoso performed the micro-CT analyses. Dr. Oran D Kennedy performed the histomorphometry 
analyses. Dr. Hector Jasper, Dr. Horacio Domené, Mrs. Liliana Karabatas, and Mrs. Clara Guida 
performed the serum IGF-1 complex-formation assay. Dr. Mitchell B Schaffler and Dr. Clifford J Rosen 
helped in data interpretation and manuscript preparation.  
 
The authors would like to thank Sonali Lahoti, Ban Zhaojiang, and Brian Sunwoo (David B. Kriser 
Dental Center, Department of Basic Science and Craniofacial Biology, New York University College of 
Dentistry, New York, NY) for technical assistance.  
 13
 
References: 
1. Yakar, S., and Adamo, M. L. (2012) Insulin-like growth factor 1 physiology: lessons from mouse 
models. Endocrinol Metab Clin North Am 41, 231-247, v 
2. Butler, A. A., Yakar, S., and LeRoith, D. (2002) Insulin-like growth factor-I: 
compartmentalization within the somatotropic axis? News Physiol Sci 17, 82-85 
3. Le Roith, D., Bondy, C., Yakar, S., Liu, J. L., and Butler, A. (2001) The somatomedin hypothesis: 
2001. Endocrine reviews 22, 53-74 
4. Yakar, S., Kim, H., Zhao, H., Toyoshima, Y., Pennisi, P., Gavrilova, O., and Leroith, D. (2005) 
The growth hormone-insulin like growth factor axis revisited: lessons from IGF-1 and IGF-1 
receptor gene targeting. Pediatric nephrology (Berlin, Germany) 20, 251-254 
5. Yakar, S., Rosen, C. J., Bouxsein, M. L., Sun, H., Mejia, W., Kawashima, Y., Wu, Y., Emerton, 
K., Williams, V., Jepsen, K., Schaffler, M. B., Majeska, R. J., Gavrilova, O., Gutierrez, M., 
Hwang, D., Pennisi, P., Frystyk, J., Boisclair, Y., Pintar, J., Jasper, H., Domene, H., Cohen, P., 
Clemmons, D., and LeRoith, D. (2009) Serum complexes of insulin-like growth factor-1 modulate 
skeletal integrity and carbohydrate metabolism. Faseb J 23, 709-719 
6. Yakar, S., Canalis, E., Sun, H., Mejia, W., Kawashima, Y., Nasser, P., Courtland, H. W., 
Williams, V., Bouxsein, M., Rosen, C., and Jepsen, K. J. (2009) Serum IGF-1 determines skeletal 
strength by regulating subperiosteal expansion and trait interactions. J Bone Miner Res 24, 1481-
1492 
7. Courtland, H. W., DeMambro, V., Maynard, J., Sun, H., Elis, S., Rosen, C., and Yakar, S. (2010) 
Sex-specific regulation of body size and bone slenderness by the acid labile subunit. J Bone Miner 
Res 25, 2059-2068 
8. Yakar, S., Rosen, C. J., Beamer, W. G., Ackert-Bicknell, C. L., Wu, Y., Liu, J. L., Ooi, G. T., 
Setser, J., Frystyk, J., Boisclair, Y. R., and LeRoith, D. (2002) Circulating levels of IGF-1 directly 
regulate bone growth and density. The Journal of clinical investigation 110, 771-781 
9. Stratikopoulos, E., Szabolcs, M., Dragatsis, I., Klinakis, A., and Efstratiadis, A. (2008) The 
hormonal action of IGF1 in postnatal mouse growth. Proceedings of the National Academy of 
Sciences of the United States of America 105, 19378-19383 
10. Wu, Y., Sun, H., Yakar, S., and LeRoith, D. (2009) Elevated levels of insulin-like growth factor 
(IGF)-I in serum rescue the severe growth retardation of IGF-I null mice. Endocrinology 150, 
4395-4403 
11. Elis, S., Courtland, H. W., Wu, Y., Rosen, C. J., Sun, H., Jepsen, K. J., Majeska, R. J., and Yakar, 
S. (2010) Elevated serum levels of IGF-1 are sufficient to establish normal body size and skeletal 
properties even in the absence of tissue IGF-1. J Bone Miner Res 25, 1257-1266 
12. Moerth, C., Schneider, M. R., Renner-Mueller, I., Blutke, A., Elmlinger, M. W., Erben, R. G., 
Camacho-Hubner, C., Hoeflich, A., and Wolf, E. (2007) Postnatally elevated levels of insulin-like 
growth factor (IGF)-II fail to rescue the dwarfism of IGF-I-deficient mice except kidney weight. 
Endocrinology 148, 441-451 
13. Zhou, Y., Xu, B. C., Maheshwari, H. G., He, L., Reed, M., Lozykowski, M., Okada, S., Cataldo, 
L., Coschigamo, K., Wagner, T. E., Baumann, G., and Kopchick, J. J. (1997) A mammalian model 
for Laron syndrome produced by targeted disruption of the mouse growth hormone 
receptor/binding protein gene (the Laron mouse). Proceedings of the National Academy of 
Sciences of the United States of America 94, 13215-13220 
14. Bikle, D., Majumdar, S., Laib, A., Powell-Braxton, L., Rosen, C., Beamer, W., Nauman, E., 
Leary, C., and Halloran, B. (2001) The skeletal structure of insulin-like growth factor I-deficient 
mice. J Bone Miner Res 16, 2320-2329 
15. Wu, Y., Liu, C., Sun, H., Vijayakumar, A., Giglou, P. R., Qiao, R., Oppenheimer, J., Yakar, S., 
and LeRoith, D. (2011) Growth hormone receptor regulates beta cell hyperplasia and glucose-
stimulated insulin secretion in obese mice. The Journal of clinical investigation 121, 2422-2426 
 14
16. Schaefer, G. B., Rosenbloom, A. L., Guevara-Aguirre, J., Campbell, E. A., Ullrich, F., Patil, K., 
and Frias, J. L. (1994) Facial morphometry of Ecuadorian patients with growth hormone receptor 
deficiency/Laron syndrome. J Med Genet 31, 635-639 
17. Phillips, J. A., 3rd (1992) Molecular biology of growth hormone receptor dysfunction. Acta 
Paediatr Suppl 383, 127-131 
18. Behncken, S. N., Rowlinson, S. W., Rowland, J. E., Conway-Campbell, B. L., Monks, T. A., and 
Waters, M. J. (1997) Aspartate 171 is the major primate-specific determinant of human growth 
hormone. Engineering porcine growth hormone to activate the human receptor. The Journal of 
biological chemistry 272, 27077-27083 
19. Souza, S. C., Frick, G. P., Wang, X., Kopchick, J. J., Lobo, R. B., and Goodman, H. M. (1995) A 
single arginine residue determines species specificity of the human growth hormone receptor. 
Proceedings of the National Academy of Sciences of the United States of America 92, 959-963 
20. Geffner, M. E., Golde, D. W., Lippe, B. M., Kaplan, S. A., Bersch, N., and Li, C. H. (1987) 
Tissues of the Laron dwarf are sensitive to insulin-like growth factor I but not to growth hormone. 
The Journal of clinical endocrinology and metabolism 64, 1042-1046 
21. Laron, Z., Anin, S., Klipper-Aurbach, Y., and Klinger, B. (1992) Effects of insulin-like growth 
factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. 
Lancet 339, 1258-1261 
22. Backeljauw, P. F., and Underwood, L. E. (1996) Prolonged treatment with recombinant insulin-
like growth factor-I in children with growth hormone insensitivity syndrome--a clinical research 
center study. GHIS Collaborative Group. The Journal of clinical endocrinology and metabolism 
81, 3312-3317 
23. Backeljauw, P. F., and Underwood, L. E. (2001) Therapy for 6.5-7.5 years with recombinant 
insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical 
research center study. The Journal of clinical endocrinology and metabolism 86, 1504-1510 
24. Guevara-Aguirre, J., Rosenbloom, A. L., Vasconez, O., Martinez, V., Gargosky, S. E., Allen, L., 
and Rosenfeld, R. G. (1997) Two-year treatment of growth hormone (GH) receptor deficiency 
with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and 
to GH-treated GH deficiency. The Journal of clinical endocrinology and metabolism 82, 629-633 
25. Mauras, N., Martinez, V., Rini, A., and Guevara-Aguirre, J. (2000) Recombinant human insulin-
like growth factor I has significant anabolic effects in adults with growth hormone receptor 
deficiency: studies on protein, glucose, and lipid metabolism. The Journal of clinical 
endocrinology and metabolism 85, 3036-3042 
26. Tonella, P., Fluck, C. E., and Mullis, P. E. (2010) Insulin-like growth factor-I treatment in primary 
growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-
binding protein-3 complex. Horm Res Paediatr 73, 140-147 
27. Guevara-Aguirre, J., Vasconez, O., Martinez, V., Martinez, A. L., Rosenbloom, A. L., Diamond, 
F. B., Jr., Gargosky, S. E., Nonoshita, L., and Rosenfeld, R. G. (1995) A randomized, double 
blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth 
factor-I in children with growth hormone receptor deficiency. The Journal of clinical 
endocrinology and metabolism 80, 1393-1398 
28. El Kholy, M., and Elsedfy, H. H. (2011) Effect of GnRH analogue on height potential in patients 
with severe growth hormone insensitivity syndrome treated with IGF-I. Journal of pediatric 
endocrinology & metabolism : JPEM 24, 983-988 
29. Klinger, B., and Laron, Z. (1995) Three year IGF-I treatment of children with Laron syndrome. 
Journal of pediatric endocrinology & metabolism : JPEM 8, 149-158 
30. Laron, Z., Klinger, B., Eshet, R., Kaneti, H., Karasik, A., and Silbergeld, A. (1993) Laron 
syndrome due to a post-receptor defect: response to IGF-I treatment. Isr J Med Sci 29, 757-763 
 15
31. Ranke, M. B., Savage, M. O., Chatelain, P. G., Preece, M. A., Rosenfeld, R. G., Blum, W. F., and 
Wilton, P. (1995) Insulin-like growth factor I improves height in growth hormone insensitivity: 
two years' results. Hormone research 44, 253-264 
32. Ooi, G. T., Cohen, F. J., Tseng, L. Y., Rechler, M. M., and Boisclair, Y. R. (1997) Growth 
hormone stimulates transcription of the gene encoding the acid-labile subunit (ALS) of the 
circulating insulin-like growth factor-binding protein complex and ALS promoter activity in rat 
liver. Molecular endocrinology 11, 997-1007 
33. Robertson, K., Lu, Y., De Jesus, K., Li, B., Su, Q., Lund, P. K., and Liu, J. L. (2008) A general 
and islet cell-enriched overexpression of IGF-I results in normal islet cell growth, hypoglycemia, 
and significant resistance to experimental diabetes. American journal of physiology. 
Endocrinology and metabolism 294, E928-938 
34. Courtland, H. W., Sun, H., Beth-On, M., Wu, Y., Elis, S., Rosen, C. J., and Yakar, S. (2011) 
Growth hormone mediates pubertal skeletal development independent of hepatic IGF-1 
production. J Bone Miner Res 26, 761-768 
35. Baxter, R. C., and Martin, J. L. (1989) Structure of the Mr 140,000 growth hormone-dependent 
insulin-like growth factor binding protein complex: determination by reconstitution and affinity-
labeling. Proceedings of the National Academy of Sciences of the United States of America 86, 
6898-6902 
36. Domene, H. M., Bengolea, S. V., Martinez, A. S., Ropelato, M. G., Pennisi, P., Scaglia, P., 
Heinrich, J. J., and Jasper, H. G. (2004) Deficiency of the circulating insulin-like growth factor 
system associated with inactivation of the acid-labile subunit gene. N Engl J Med 350, 570-577 
37. Elis, S., Wu, Y., Courtland, H. W., Cannata, D., Sun, H., Beth-On, M., Liu, C., Jasper, H., 
Domene, H., Karabatas, L., Guida, C., Basta-Pljakic, J., Cardoso, L., Rosen, C. J., Frystyk, J., and 
Yakar, S. (2011) Unbound (bioavailable) IGF1 enhances somatic growth. Dis Model Mech 4, 649-
658 
38. Bouxsein, M. L., Boyd, S. K., Christiansen, B. A., Guldberg, R. E., Jepsen, K. J., and Muller, R. 
(2010) Guidelines for assessment of bone microstructure in rodents using micro-computed 
tomography. J Bone Miner Res 25, 1468-1486 
 
 
 16
 
Figure legends: 
 
Figure 1: Generation and validation of the GHRKO-HIT mouse model. (A) Schematic diagram of the 
rat Igf-1 (R-IGF-1) transgenic construct used to drive Igf-1 expression specifically in the liver under the 
TTR promoter. (B) Schematic diagram of the breeding strategy used to generate control GHRKO, 
GHRKO-HIT and HIT mice. GHR hemizygous mice (W/-) were crossed with HIT transgenic mice to 
generate W/-/HIT mice. Crossing of the W/-/HIT offspring gave rise to the desired genotypes. (C) 
Analyses of gene expression in liver, muscle and fat tissues dissected from control GHRKO, GHRKO-
HIT and HIT mice. RT-PCR was used to detect the expression levels of RnIgf-1 (rat Igf-1 transgene), 
MmIgf-1 (mouse Igf-1), Als (acid labile subunit), Ghr (growth hormone receptor), and Igfbp-3 (Igf-
binding protein-3). 
 
Figure 2: GHR action is essential for the establishment of body size. Body weights of male (A) and 
female (B) mice on the C57Bl6/J genetic background (n>20 mice per group genotype and age) and of 
male (C) and female (D) mice on the FVB/N genetic background (n>20 mice per group genotype and age) 
were followed from 3 to 16 weeks of age. Relative weights of gonadal-, subcutaneous- (S.C.) and brown-
fat pads at 16 weeks of age in male mice (E) (n>20 mice per group genotype and age). Female mice 
showed similar results. Data are presented as the mean+/-SEM, and significance was determined at 
p<0.05. * significantly different from control. 
 
Figure 3: GHR regulates the endocrine pool of IGF-1. (A) Serum IGF-1 levels (n=10 mice per group 
genotype) and (B) ALS immunoreactivity in sera from control GHRKO, GHRKO-HIT and HIT mice 
(n=5 mice per group genotype). Serum from ALS null (ALSKO) mice was used as a negative control. (C) 
Plasma IGFBP-3 levels (n=10 mice per group genotype). (D) Formation of IGF complexes in sera from 
control GHRKO, GHRKO-HIT and HIT mice. Eluted fractions 1-10 represent ternary complexes of IGF-
1/IGFBP-3/ALS, fractions 20-30 IGF represent binary complexes of IGF-1/IGFBP, and fractions 40-50 
represent the unbound IGF-1 isotope (n=5 mice per group genotype). (E) Area under the curve of 
fractions 1-10, representing IGF-1 ternary complexes. Data are presented as the mean+/-SEM, and 
significance was determined at p<0.05. * significantly different from control. 
 
Figure 4: Serum IGF-1 does not restore the skeletal defects of GHRKO mice. (A) mCT images taken 
at the femoral midshaft (cortical bone) or at the distal femur (trabecular bone) of control GHRKO, 
GHRKO-HIT and HIT mice. (B) Histological plastic sections (50 μm) of cortical bone taken at the 
femoral midshaft.  
 
Figure 5: GHRKO and GHRKO-HIT mice show significant reductions in skeletal Igf-1 gene 
expression. Femurs were dissected from 16 week-old mice. Marrow from the mid-diaphysis area flushed 
and RNA extracted from the cortical shells. (A) Igf-1 gene expression (assessed by real-time PCR) 
significantly decreased in GHRKO and GHRKO-HIT mice (n=5 mice per group genotype). (B) Ghr gene 
expression (assessed by real-time PCR) was undetectable in cortical bone RNA extracts from GHRKO 
and GHRKO-HIT mice. Data presented as mean+/-SEM of n=5 mice per group genotype and significance 
was determined at p<0.05, NS- not significant, * significantly different from control. 
 
 
Figure 6: Serum IGF-1 restores β-cell mass and glucose tolerance in GHRKO mice. Fasting glucose 
levels (A) and serum insulin levels (B) were measured at 16 weeks of age. A glucose tolerance test (C) 
was performed in adult male mice at 14-16 weeks of age. β-cell mass (D) was assessed in pancreatic 
sections immunostained with an anti-insulin antibody. β-cell mass was calculated as the β-cell relative 
 17
area multiplied by the pancreatic weights of 6 mice per group. Representative images of pancreatic β-
islets immunostained with an anti-insulin antibody.  Data are presented as the mean+/-SEM, and 
significance was determined at p<0.05. NS- not significant, * significantly different from control. 
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Table 1: Body weight, body length and organ weights of control, HIT, GHRKO and GHRKO-HIT male 
mice at 16 weeks of age (C57Bl6/j background). 
 
 Control (n=12) HIT (n=13) GHRKO (n=10) GHRKO-HIT 
(n=7) 
Body weight, g 29.26+/-1.08 bcd 31.99+/-0.36abcd 15.85+/-0.77 abd 20.43+/-1.06 abc 
Body length, cm 10.24+/-0.04 cd 10.38+/-0.07 cd 7.66+/-0.06 abd 8.48+/-0.11 abc 
Liver, g  
(% body weight) 
1.31+/-0.06 
(4.34+/-0.16) c 
1.48+/-0.05 
(4.61+/-0.15) c 
0.56+/-0.02 
(3.58+/-0.10) 
0.86+/-0.04 
(4.24+/-0.12) c 
Muscle, g  
(% body weight) 
0.35+/-0.01 
(1.21+/-0.05)cd 
0.39+/-0.01 
(1.24+/-0.03) cd 
0.13+/-0.00 
(0.87+/-0.05) ab 
0.2+/-0.01  
(0.98+/-0.05) ab 
Gonadal fat, g  
(% body weight) 
0.49+/-0.05 
(1.77+/-0.15) b 
0.35+/-0.04 
(1.11+/-0.14) ac 
0.37+/-0.05 
(2.29+/-0.22) bd 
0.30+/-0.05 
(1.42+/-0.18) c 
Brown fat, g  
(% body weight) 
0.07+/-0.00 
(0.22+/-0.00) cd 
0.07+/-0.00 
(0.20+/-0.02) cd 
0.07+/-0.02 
(0.45+/-0.10) ab 
0.10+/-0.01 
(0.44+/-0.04) ab 
Kidney, g  
(% body weight) 
0.38+/-0.01 
(1.29+/-0.03) bcd 
0.46+/-0.01 
(1.46+/-0.04) acd 
0.13+/-0.00 
(0.83+/-0.03) abd 
0.24+/-0.00 
(1.20+/-0.03) abc 
Spleen, g  
(% body weight) 
0.09+/-0.00 
(0.32+/-0.03) bcd 
0.16+/-0.01 
(0.50+/-0.04) acd 
0.03+/-0.00 
(0.17+/-0.01) abd 
0.08+/-0.00 
(0.38+/-0.02) abc 
Heart, g  
(% body weight) 
0.15+/-0.01 
(0.50+/-0.03) cd 
0.17+/-0.00 
(0.51+/-0.02) cd 
0.07+/-0.00 
(0.42+/-0.02) ab 
0.08+/-0.00 
(0.40+/-0.03) ab 
Lung, g  
(% body weight) 
0.16+/-0.00 
(0.57+/-0.02) 
0.18+/-0.00 
(0.54+/-0.01) 
0.09+/-0.00 
(0.54+/-0.01) 
0.11+/-0.00 
(0.55+/-0.05) 
a- significantly different from controls 
b- significantly different from HIT 
c- significantly different from GHRKO 
d- significantly different from GHRKO-HIT 
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Table 2: Cortical bone analyses performed by mCT at the femoral midshaft of control, HIT, GHRKO and 
GHRKO-HIT mice at 16 weeks of age (C57Bl6/J background). Data are presented as the mean+/-SD, 
p<0.05. 
 
Control 
(n=14) 
GHRKO  
(n=9) 
GHRKO-HIT 
(n=11) 
HIT  
(n=9) 
Cortical bone 
Male 
Femur length (Le), mm 15.12+/-0.26 10.44+/-0.67abd 12.01+/-0.25abc 15.25+/-0.25cd 
Tt.Ar, mm2 1.81+/-0.20 1.13+/-0.38abd 1.24+/-0.12abc 1.86+/-0.22cd 
Ct.Ar, mm2 0.86+/-0.05 0.39+/-0.09abd 0.55+/-0.09abc 0.86+/-0.14cd 
Ma.Ar, mm2 0.91+/-0.2 0.73+/-0.28abd 0.68+/-0.15ab 1.01+/-0.12cd 
Ct.Th, mm 0.16+/-0.01 0.10+/-0.02abd 0.14+/-0.01abc 0.15+/-0.02cd 
RCA 0.48+/-0.05 0.36+/-0.06abd 0.44+/-0.08c 0.45+/-0.04d 
J0, mm4 0.44+/-0.05 0.11+/-0.04abd 0.18+/-0.05abc 0.46+/-0.13cd 
Robustness (Tt.Ar/Le) 0.11+/-0.01 0.08+/-0.01ab 0.09+/-0.00ab 0.12+/-0.01cd 
Female  
Control 
(n=6) 
GHRKO 
(n=9) 
GHRKO-HIT 
(n=8) 
HIT 
(n=12) 
Femur length (Le), mm 15.03+/-0.36 11.29+/-0.73abd 12.75+/-0.00abc 15.10+/-0.17cd 
Tt.Ar, mm2 1.61+/-0.14 0.91+/-0.22abd 1.51+/-0.23abc 1.71+/-0.26cd 
Ct.Ar, mm2 0.74+/-0.06 0.37+/-0.10abd 0.63+/-0.04abc 0.79+/-0.03cd 
Ma.Ar, mm2 0.94+/-0.21 0.53+/-0.15abd 0.87+/-0.22bc 0.91+/-0.24cd 
Ct.Th, mm 0.16+/-0.00 0.11+/-0.01abd 0.16+/-0.00bc 0.17+/-0.00cd 
RCA 0.45+/-0.04 0.41+/-0.06abd 0.43+/-0.06bc 0.47+/-0.06cd 
J0, mm4 0.31+/-0.05 0.09+/-0.05abd 0.20+/-0.03abc 0.33+/-0.03cd 
Robustness (Tt.Ar/Le) 0.10+/-0.00 0.08+/-0.02abd 0.09+/-0.00abc 0.10+/-0.01cd 
a- significantly different from controls 
b- significantly different from HIT 
c- significantly different from GHRKO 
d- significantly different from GHRKO-HIT 
 
 20
Table 3: Trabecular bone parameters assayed by mCT at the distal femur of control, HIT, GHRKO and 
GHRKO-HIT mice at 16 weeks of age (C57Bl6/J background). Data are presented as the mean+/-SD, 
p<0.05. 
 
Control  
(n=7) 
GHRKO  
(n=8) 
GHRKO-HIT  
(n=11) 
HIT  
(n=9) 
Trabecular 
bone 
Male 
BV/TV, % 8.48+/-2.83 5.77+/-3.15 b 5.58+/-2.30 ab 10.62+/-2.90 acd 
Tb.Th, μm 48.51+/-3.53 43.55+/-10.29  50.16+/-6.40  47.87+/-3.29  
Tb.N, 1/mm 1.7x10-3+/-0.4x10-3 1.2x10-3+/-0.4x10-3 b 1.1x10-3+/-0.4x10-3 ab 2.2x10-3+/-0.5x10-3 cd
Tb.Sp, μm 234.13+/-21.30 261.56+/-43.10 b 282.46+/-48.85 ab 201.68+/-31.31 acd 
BMD, g/cc 0.20+/-0.04 0.11+/-0.02 abd 0.15+/-0.03 acd 0.21+/-0.04 cd 
Female  
Control 
(n=6) 
GHRKO 
(n=8) 
GHRKO-HIT 
(n=8) 
HIT 
(n=12) 
BV/TV, % 3.01+/-1.2 2.03+/-1.28 d 5.43+/-1.59 acd 2.77+/-0.71 d 
Tb.Th, μm 45.04+/-4.55 39.64+/-6.64  51.73+/-5.33  44.63+/-3.66  
Tb.N, 1/mm 0.6x10-3+/-0.2x10-3 0.5x10-3+/-0.2x10-3  1.0x10-3+/-0.2x10-3  0.6x10-3+/-0.1x10-3 
Tb.Sp, μm 301.93+/-31.16 345.61+/-39.80 bd 262.96+/-28.64 cd 298.25+/-20.98 cd 
BMD, g/cc 0.10+/-0.02 0.08+/-0.02 abd 0.14+/-0.00 acd 0.11+/-0.01 c 
a- significantly different from controls 
b- significantly different from HIT 
c- significantly different from GHRKO 
d- significantly different from GHRKO-HIT 
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Table 4: Histomorphometry data from mid-diaphyseal cortical bone of female mice (on C57Bl/6 
background) at 16 weeks of age. Values are the mean ± S.D., p<0.05. Calcein labels were 
injected twice in intervals of 10-14 days. In GHRKO and the GHRKO-HIT mice the intervals 
between injections were 17-23 days. 
 
Surface Parameter Control GHRKO GHRKO-HIT HIT 
MS/BS, % 45.34+/-7.13 39.88+/-30.49 65.95+/-19.79 71.14+/-10.89 
MAR, um/day 0.59+/-0.56 0.30+/-0.40 0.75+/-0.04 0.97+/-0.34 
Endosteal  
BFR, 
um/day*100 
29.96+/-29.18 21.83+/-34.01 49.69+/-15.38 67.14+/-26.40 
MS/BS, % 33.96+/-16.42 1.93+/-3.31 23.85+/-15.13 28.53+/-15.44 
MAR, um/day 0.76+/-0.45 0.00+/-0.00 0.68+/-0.61 0.53+/-0.61 
Periosteal  
BFR, 
um/day*100 
29.66+/-21.48 0.00+/-0.00 22.54+/-21.68 19.82+/-24.25 
 
 
 
 
Figure 1 
 
 22
 
Figure 2 
 
 
 23
 
Figure 3 
 
 
 
 24
 
Figure 4 
 
 
 
 25
 
Figure 5 
 
 26
 
Figure 6 
 
 
 27
